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Rituximab	 is	 a	MAb	 against	 human	 CD20	 thus	 not	 binding	 to	 canine	
CD20.	 New	 therapeu0c	MAbs	 have	 been	 developed,	 such	 as	 AT-004	
(Aratana	 Therapeu0cs	 Inc.)	 which	 bind	 speciﬁcally	 to	 canine	 CD20	
(Figure	1).	Studies	show	longer	median	progression-free	survival	(PFS)	
and	 overall	 survival	 (OS)	 0mes	 in	 animals	 treated	 with	 an0-canine	
CD20	MAb	(Figure	2).	
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Figure	2.	Median	PFS	(A)	and	OS	(B)	0mes	in	animals	treated	
with	MAb	or	placebo	[1].	
